Armata Pharmaceuticals wins new U.S. patents for AP-SA02, AP-PA02 phage programs

Armata Pharmaceuticals secured two newly issued U.S. patents covering bacteriophage candidates AP-SA02 and AP-PA02. Patents extend expected U.S. protection to at least February 2041 for AP-SA02 and about January 2043 for AP-PA02.